Discover how Evelo’s EDP1815 may prevent the progression of COVID-19.
Learn More
Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
